You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
Colorcon
Merck
Express Scripts

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Patent: 9,109,255

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,109,255
Title:Methods and compositions for determining responsiveness to antibody therapy
Abstract: Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable Fc.gamma.R polymorphism, e.g., the 131 H/H genotype or the 158 V/V genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.
Inventor(s): Levy; Ronald (Stanford, CA), Weng; Wen-Kai (Saratoga, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Application Number:11/155,308
Patent Claims:see list of patent claims

Details for Patent 9,109,255

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2024-06-18 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2024-06-18 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2024-06-18 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2024-06-18 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Baxter
Boehringer Ingelheim
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.